Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revanesse is a brand of hyaluronic acid-based dermal fillers used for cosmetic purposes. The primary active ingredient is hyaluronic acid, a naturally occurring polysaccharide found in the human body that helps maintain skin hydration and volume. In the context of dermal fillers, hyaluronic acid is produced by bacterial fermentation and then purified for use as an injectable soft tissue filler. The mechanism of action involves injection into facial tissues to restore volume, smooth moderate to severe wrinkles and folds (such as nasolabial folds), or augment lips. Some formulations (e.g., Revanesse Lips+) are crosslinked with 1,4-butanediol diglycidyl ether (BDDE) to enhance stability and longevity; certain products also contain lidocaine for pain reduction during injection[2][3][4]. Revanesse products are FDA approved for adults aged 22 years or older seeking correction of facial wrinkles/creases or lip augmentation[2][3][4]. Results typically last up to one year.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Revanesse.